Psychoactive fungi

Global Behavioral Health Market Where Psychedelics Have Shown Tremendous Potential Could Hit $240 Billion By 2026

Retrieved on: 
Tuesday, March 2, 2021

It is not a way to get higher 'highs' in the legal cannabis market it will make its mark in medicine.

Key Points: 
  • It is not a way to get higher 'highs' in the legal cannabis market it will make its mark in medicine.
  • A report from the CFN Media Group, said: "The global behavioral health market, where psychedelics have shown tremendous potential, could hit $240 billion by 2026, according to Acumen Research and Consulting.
  • Given the ineffectiveness of many existing treatments, psychedelics have blue sky potential in the space.
  • Health Canada recently granted exemptionsto a number of healthcare professionals who wanted to possess and consume psilocybin mushrooms.

Global Behavioral Health Market Where Psychedelics Have Shown Tremendous Potential Could Hit $240 Billion By 2026

Retrieved on: 
Tuesday, March 2, 2021

It is not a way to get higher 'highs' in the legal cannabis market it will make its mark in medicine.

Key Points: 
  • It is not a way to get higher 'highs' in the legal cannabis market it will make its mark in medicine.
  • A report from the CFN Media Group, said: "The global behavioral health market, where psychedelics have shown tremendous potential, could hit $240 billion by 2026, according to Acumen Research and Consulting.
  • Given the ineffectiveness of many existing treatments, psychedelics have blue sky potential in the space.
  • Health Canada recently granted exemptionsto a number of healthcare professionals who wanted to possess and consume psilocybin mushrooms.

OPTIMI HEALTH and NUMINUS WELLNESS to Conduct Psychedelic Lab Research and Development

Retrieved on: 
Tuesday, March 2, 2021

Optimi applied for and has received a research exemption from Health Canada allowing it to conduct research activities involving psychedelic compounds, specifically psilocybin and psilocin.

Key Points: 
  • Optimi applied for and has received a research exemption from Health Canada allowing it to conduct research activities involving psychedelic compounds, specifically psilocybin and psilocin.
  • Optimi has further applied for and is awaiting approval of a dealers license necessary to undertake certain additional aspects of its research and development.
  • The Company has elected to move ahead by undertaking several research and development projects with Numinus specifically related to Psilocybe mushrooms, psychedelic compounds, and formulations within their licensed facilities.
  • Numinus Wellness Inc. is a health care and research company creating psychedelic-centered solutions to treat mental illness, substance abuse and trauma.

Medical Breakthroughs Propel Psilocybin Closer to Legalization

Retrieved on: 
Monday, March 1, 2021

For example, earlier in 2019, Colorado became the first state to decriminalize magic mushrooms (mushrooms containing psilocybin).

Key Points: 
  • For example, earlier in 2019, Colorado became the first state to decriminalize magic mushrooms (mushrooms containing psilocybin).
  • Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
  • 'Mindleap's software patents will strengthen our intellectual property portfolio overall which now totals 8 patent filings currently in process.'
  • The Mindleap platform brings convenience, improves access to treatments and can lead to more personal breakthroughs.

Medical Breakthroughs Propel Psilocybin Closer to Legalization

Retrieved on: 
Monday, March 1, 2021

For example, earlier in 2019, Colorado became the first state to decriminalize magic mushrooms (mushrooms containing psilocybin).

Key Points: 
  • For example, earlier in 2019, Colorado became the first state to decriminalize magic mushrooms (mushrooms containing psilocybin).
  • Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
  • 'Mindleap's software patents will strengthen our intellectual property portfolio overall which now totals 8 patent filings currently in process.'
  • The Mindleap platform brings convenience, improves access to treatments and can lead to more personal breakthroughs.

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain

Retrieved on: 
Monday, March 1, 2021

This is the first and only solidified commercial supply chain of psilocybin mushrooms and we believe this supply chain will open up many doors to potentially collaborate and participate in initiatives that we find potentially promising, said Joshua Bartch, CEO and Chairman of Mydecine.

Key Points: 
  • This is the first and only solidified commercial supply chain of psilocybin mushrooms and we believe this supply chain will open up many doors to potentially collaborate and participate in initiatives that we find potentially promising, said Joshua Bartch, CEO and Chairman of Mydecine.
  • This marks a milestone of fulfilling on the promise of creating a fully vertical and uninterrupted global supply chain.
  • This supply chain will give us unrestrictive scalable access including numerous types of unique psychedelic mushroom species native to Jamaica.
  • Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply.

Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process

Retrieved on: 
Monday, February 22, 2021

pharmaceutical grade) psilocybin utilizing Mindset's innovative and cost-effective patent-pending synthesis process.

Key Points: 
  • pharmaceutical grade) psilocybin utilizing Mindset's innovative and cost-effective patent-pending synthesis process.
  • Mindset anticipates that there will be significant demand for its proprietary, high-quality psilocybin supply given the increasing number of trials and studies underway utilizing psilocybin.
  • Several CDMOs that specialize in psilocybin synthesis have exclusive relationships with individual clients, further narrowing the range of psilocybin supply options.
  • Mindset's novel synthesis process meets an increasing need from the growing medical psychedelic space for a reliable source of affordable, pharmaceutical grade psilocybin.

Minerco Inc., The Magic Mushroom Company, Addresses Speculative Rumors and Information Circulating Social Media Platforms

Retrieved on: 
Friday, February 19, 2021

Company will host an open SHROOM ZOOM this Sunday at 5 PM EST for MINERS and others invited

Key Points: 
  • To respond, the company is committed in addressing these rumors to MINERS.
  • During this Sunday's Shroom Zoom Call, Minerco Inc's primary focus will still be on company goals, but they are planning on addressing these rumors with attendees.
  • "FEAR ('False Evidence Appearing Real') is a key to understanding why we will entertain a call concerning these alleged rumors.
  • The Magic Mushroom Company (OTC: MINE) is the pioneering company specializing in the research, production, and distribution of psilocybin mushroom products ("Magic Mushrooms'').

Minerco Inc., The Magic Mushroom Company, Paid Off Old Debt to Creditor EROP Capital

Retrieved on: 
Tuesday, February 16, 2021

As part of their settlement,477,000,000 shares will be returned to the company's treasury

Key Points: 
  • Atlanta, Georgia--(Newsfile Corp. - February 16, 2021) - Minerco Inc. (OTC Pink: MINE) inherited EROP Capital's debt that had been accrued from previous ownership.
  • As a result, Minerco's new management team met with EROP Capital and completed debt settlement.
  • In the aftermath of settling EROP's debt, Minerco's management also made a corporate decision to retire 477,000,000 shares back to the company's treasury.
  • The Magic Mushroom Company (OTC Pink: MINE) is the pioneering company specializing in the research, production, and distribution of psilocybin mushroom products ("Magic Mushrooms'').

ATMA Launches Canada's First Psychedelic Training Program for Mental Health Professionals that Includes a Legal Psychedelic Experience

Retrieved on: 
Friday, February 12, 2021

Starting in March 2021, ATMA and Wayfoundwill present the Psychedelic Therapy Training Program for Mental Health Professionals, which will take place through remote training as well as on-site at ATMA's Calgary Journey Center.

Key Points: 
  • Starting in March 2021, ATMA and Wayfoundwill present the Psychedelic Therapy Training Program for Mental Health Professionals, which will take place through remote training as well as on-site at ATMA's Calgary Journey Center.
  • The training allows participants to apply for an exemption from Health Canada to experience legal psychedelic-assisted therapy using psilocybin, one of the active compounds found in 'magic mushrooms'.
  • Incorporating hands-on experience with psychedelics for therapists in a legal setting is a first for the mental health community in Canada.
  • Each participant of the professional training program will also be assisted in obtaining their own exemption from Health Canada so that they may personally undergo psychedelic-assisted therapy.